Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Turkey Diabetes Market Report and Forecast

491 views

Published on

Published in: Business
  • Be the first to comment

  • Be the first to like this

Turkey Diabetes Market Report and Forecast

  1. 1. About IMARCFor more than 5 years, the International Market Analysis Research and Consulting Group hasbeen a leading advisor on management strategy and market research worldwide. We partnerwith clients in all sectors and regions to identify their highest-value opportunities, address theirmost critical challenges, and transform their businesses.IMARCs information products include major market, scientific, economic and technologicaldevelopments for business leaders in pharmaceutical, industrial, and high technologyorganizations. Market forecasts and industry analysis for biotechnology, advanced materials,pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processingmethods are at the top of the companys expertise.IMARC’s tailored approach combines unfathomable insight into the dynamics of companies andmarkets with close cooperation at all levels of the client organization. This ensures that ourclients achieve unmatchable competitive advantage, build more proficient organizations, andsecure lasting results.imarc©
  2. 2. About The ReportIMARC’s new report “Turkey Diabetes Market Report & Forecast 2011-2016” provides ananalytical and statistical insight into the Turkish diabetes market. The report provides bothcurrent and future trends in the prevalence of diabetes in Turkey and its demographicalbreakup. The report has segmented the Turkish diabetes market into two segments – Insulinand the Oral Antidiabetics market. For each of the aforementioned categories, the reportprovides historical and future market sales of key classes, key companies, key drugs and keymolecules.The research study serves as an exceptional tool to understand the market trends,therapeutic structure, competitive structure and the outlook of the Turkish diabetes markettill 2016. This report can serve as an excellent guide for investors, researchers, consultants,marketing strategists and all those who are planning to foray into Turkish diabetes market insome form or the other.Key Questions Answered in this Report: What is the current size and demographic breakup of the diabetes population in Turkey and what is its future outlook? How has the total diabetes market behaved since 2005 and what are the expected trends till 2016? What has been the historical performance of the Turkish Insulin market from 2005-2010 and its outlook for 2016? What has been the performance of top classes, top players, top molecules and top drugs between 2005-2010 in the Insulin market? What has been the historical performance of the Oral Antidiabetics market from 2005- 2010 and its outlook for 2016? What has been the performance of top classes, top players, top molecules and top drugs between 2005-2010 in the Oral Antidiabetics market?Why should you buy this report? Gain a deeper understanding about the prevalence and demographical breakup of diabetes in Turkey and identify your potential patient pool.imarc©
  3. 3. Analyze the historical, current and future trends in the Insulin and Oral Antidiabetic markets and identify potential classes, drugs, partners and competitors for market entry and expansion plans. Develop Investment strategies by identifying companies that have been the biggest winners and losers in the Turkish Insulin and Oral Antidiabetic markets. Gain an insight into future market events such as new product launches.Classes Covered: Fast acting Insulin, Long acting Insulin, Intermediate and Fast acting Insulin,Intermediate acting Insulin, Biguanide Antidiabetics, Glinide Antidiabetics, SulphonylureaAntidiabetics, Glitazone Antidiabetics, DPP-IV Inhibitor Antidiabetics, Glp-1 AgonistAntidiabetics, Alpha-Glucosidase Inhibitor Antidiabetics, DPP-IV Inhibitor and BiguanideAntidiabetic Combinations, Biguanide and Glitazone Antidiabetic Combinations, DPP-IVInhibitor and Glitazone Antidiabetic Combinations, SGLT Inhibitors, SGLT Inhibitor andBiguanide Antidiabetic Combinations.Information Sources: Information has been sourced from Primary and Secondary research: Primary sources include industry surveys and face to face/telephone interviews with physicians and industry experts. Secondary sources include paid databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, Industry Portals, government sources and access to more than 4000 paid databases.Forecasting Methodology: IMARC generates its product and market forecast utilizing itsextensive database of economic and sector specific data. The initial baseline forecast isgenerated with the most recent market data. After an initial baseline forecast, all futuremacroeconomic and sector specific events and assumptions are taken into account togenerate the final forecast.imarc©
  4. 4. Table of Contents1 Executive Summary.............................................................................................. 102 Epidemiology ........................................................................................................ 12 2.1 Total Diabetes Patients .............................................................................................. 12 2.2 Patients by Gender ..................................................................................................... 13 2.3 Patients by Age Group ............................................................................................... 14 2.4 Patients by Region ..................................................................................................... 153 Market Dynamics .................................................................................................. 17 3.1 Diabetes Market .......................................................................................................... 17 3.1.1 Current Trends (2005–2010) ................................................................................. 17 3.1.2 Market Forecast (2011-2016) ................................................................................ 18 3.2 Insulin Market ............................................................................................................. 20 3.2.1 Current Trends (2005-2010) .................................................................................. 20 3.2.1.1 Market by Class ............................................................................................. 21 3.2.1.2 Market by Molecule ........................................................................................ 22 3.2.1.3 Top Players .................................................................................................... 24 3.2.1.4 Top Drugs ...................................................................................................... 26 3.2.2 Market Forecast (2011-2016) ................................................................................ 28 3.3 Oral Antidiabetics ....................................................................................................... 30 3.3.1 Current Trends (2005-2010) .................................................................................. 30 3.3.1.1 Market by Class ............................................................................................. 31 3.3.1.2 Top Players .................................................................................................... 33 3.3.1.3 Top Drugs ...................................................................................................... 34 3.3.2 Market Forecast (2011-2016) ................................................................................ 37imarc©
  5. 5. LIST OF FIGURESFigure 2-1: Turkey: Number of Diabetes Patients* (000’s), 2010, 2015, 2020, 2025 & 2030 ....................................... 12Figure 2-2: Turkey: Breakup of Diabetes Patients* by Gender (000’s), 2010, 2015, 2020, 2025 & 2030..................... 13Figure 2-3: Turkey: Breakup of Diabetes Patients* by Gender (in %), 2010, 2015, 2020, 2025 & 2030 ...................... 13Figure 2-4: Turkey: Breakup of Diabetes Patients* by Age Group (000’s), 2010, 2015, 2020, 2025 & 2030 ............... 14Figure 2-5: Turkey: Breakup of Diabetes Patients* by Age Group (in %) 2010, 2015, 2020, 2025 & 2030 .................. 14Figure 2-4: Turkey: Breakup of Diabetes Patients* by Region (000’s), 2010, 2015, 2020, 2025 & 2030 ..................... 15Figure 2-6: Turkey: Breakup of Diabetes Patients* by Region, (in %), 2010, 2015, 2020, 2025 & 2030 ...................... 16Figure 3-1: Turkey: Diabetes Market (in Million US$), 2005-2010................................................................................ 17Figure 3-2: Turkey: Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2005-2010 ............................ 18Figure 3-3: Turkey: Diabetes Market Forecast (in Million US$), 2011-2016 ................................................................. 18Figure 3-4: Turkey: Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2011-2016 ............................ 19Figure 3-5: Turkey: Insulin Market (in Million US$), 2005-2010 ................................................................................... 20Figure 3-6: Turkey: Insulin Market: Share by Class (in %), 2005-2010 ....................................................................... 21Figure 3-7: Turkey: Insulin Market: Share by Molecule (in %), 2005-2010 ................................................................... 23Figure 3-8: Turkey: Insulin Market: Share of Key Players (in %), 2005-2010 ............................................................... 25Figure 3-9: Turkey: Insulin Market: Share of Key Drugs (in %), 2005-2010 ................................................................. 28Figure 3-10: Turkey: Insulin Market Forecast (in Million US$), 2011-2016 .................................................................. 29Figure 3-11: Turkey: Oral Antidiabetics Market (in Million US$), 2005-2010 ................................................................ 30Figure 3-12: Turkey: Oral Antidiabetics Market: Share by Class (in %), 2005-2010 .................................................... 32Figure 3-13: Turkey: Oral Antidiabetics Market: Share of Key Players (in %), 2005-2010 ........................................... 34Figure 3-14: Turkey: Oral Antidiabetics Market: Share of Key Drugs (in %), 2005-2010 ............................................ 36Figure 3-15: Turkey: Oral Antidiabetics Market Forecast (in Million US$), 2011-2016 ................................................. 37Figure 3-16: Turkey: Oral Antidiabetics Market: Share by Class Forecast (in %), 2010, 2013 & 2016 ........................ 39imarc©
  6. 6. List of FiguresTable 1-1: Turkey: Oral Antidiabetics & Insulin Market Definitions ................................................................................. 8Table 3-1: Turkey: Insulin Market: Sales by Class (in Million US$), 2005-2010 ........................................................... 21Table 3-2: Turkey: Insulin Market: Sales by Molecule (in Million US$), 2005-2010...................................................... 22Table 3-3: Turkey: Insulin Market: Sales of Key Players (in Million US$), 2005-2010.................................................. 25Table 3-4: Turkey: Insulin Market: Sales of Key Drugs (in Million US$), 2005-2010 .................................................... 27Table 3-5: Turkey: Oral Antidiabetics Market: Sales by Class (in Million US$), 2005-2010 ......................................... 31Table 3-6: Turkey: Oral Antidiabetics Market: Sales of Key Players (in Million US$), 2005-2010 ................................ 34Table 3-7: Turkey: Oral Antidiabetics Market: Sales of Key Drugs (in Million US$), 2005-2010 .................................. 35Table 3-8: Turkey: Oral Antidiabetics Market: New Drug Launches (2011-2016) ........................................................ 38Table 3-9: Turkey: Oral Antidiabetics Market: Sales by Class Forecast (in Million US$), 2010, 2013 & 2016 ............. 38imarc©
  7. 7. Prices and Order Information Electronic Access Electronic Access CD-ROM Mail Delivery Hard Copy Mail Delivery(Single User License) (Multi User License) (Single User License) (Single User License) US$ 750 US$ 1300 US$ 900 US$ 900 For more information visit: http://www.imarcgroup.com/turkey-diabetes-market-report-forecast-2011- 2016/ To buy the complete report or to get a free sample: Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America) Email:sales@imarcgroup.com

×